marked.bio

MEK inhibitor ยท small molecule

luvometinib

2 active trials across 3 of our biomarkers, targeting MEK1/2. Not approved for any biomarker on marked.bio yet.

Also known as FCN-159.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 1 Phase 3
KRAS G12C 1 1 Phase 2
KRAS G12D 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of luvometinib.

  1. Fosun Pharma 2

Trials

2 of 2 trials shown

  1. FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

    Not yet recruiting Phase 3 Fosun Pharma Started 2025Primary completion 2027-04 NCT07004075

    luvometinibcarboplatintemozolomide

    KIAA1549-BRAF fusion or BRAF V600E mutation-positive.

    BRAF V600ELow-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration

  2. A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

    Recruiting Phase 2 Fosun Pharma Started 2026Primary completion 2029-06 NCT07562581

    luvometinibanlotinib

    KRAS mutation positive.

    KRAS G12CKRAS G12DNon-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted